A randomized controlled trial to assess the efficacy of an interactive mobile messaging intervention for underserved smokers: Project ACTION
1 Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, P.O. Box 301439, Unit 1330, Houston, TX, 77030-1439, USA
2 Department of Health Disparities Research, The University of Texas MD Anderson Cancer Center, P.O. Box 303906, Unit 1440, Houston, TX, 77030-3906, USA
3 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, P.O. Box 301402, Unit 1411, Houston, TX, 77230-1402, USA
BMC Public Health 2012, 12:696 doi:10.1186/1471-2458-12-696Published: 25 August 2012
Despite a significant decrease in smoking prevalence over the past ten years, cigarette smoking still represents the leading cause of preventable morbidity and mortality in the United States. Moreover, smoking prevalence is significantly higher among those with low levels of education and those living at, or below, the poverty level. These groups tend to be confronted with significant barriers to utilizing more traditional smoking cessation intervention approaches. The purpose of the study, Project ACTION (Adult smoking Cessation Treatment through Innovative Outreach to Neighborhoods), is to utilize a mobile clinic model, a network of community sites (i.e., community centers and churches) and an interactive mobile messaging system to reach and deliver smoking cessation treatment to underserved, low-income communities.
We are using a group-randomized design, with the community site as the sampling unit, to compare the efficacy of three smoking cessation interventions: 1)
- Standard Care
- Enhanced Care
- Intensive Care
It is hypothesized that the intensive care approach will most successfully address the needs of the target population and result in the highest smoking cessation rates. In addition to increasing cessation rates, the intervention offers several features (including neighborhood outreach and use of mHealth technology) that are likely to reduce treatment barriers while enhancing participant engagement and retention to treatment.
This randomized controlled trial is registered with clinicaltrials.gov registration number NCT00948129.